Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02625428 · ClinicalTrials.gov registry record · Phase 4
IRB 14-009240, Does CEUS Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys?
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT02625428: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT02625428 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02625428, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a pilot study to investigate whether contrast-enhanced ultrasound (CEUS) may help evaluate segmental differences in renal perfusion better than Doppler Ultrasound and thus help direct the biopsy to the most abnormal part of the renal cortex. This should maximize detection and increase the odds of demonstrating the true grade/severity of the histopathological abnormality.
Interventions
- DIAGNOSTIC_TEST Contrast-enhanced ultrasound (CEUS)
- DRUG Optison
- DIAGNOSTIC_TEST Ultrasound (US)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-11 |
| Est. Completion | 2019-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02625428
The ClinicalTrials.gov registry entry for NCT02625428 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Contrast-enhanced ultrasound (CEUS) is the first listed.
NCT02625428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02625428 about?
NCT02625428 is a clinical study titled "IRB 14-009240, Does CEUS Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys?". This is a pilot study to investigate whether contrast-enhanced ultrasound (CEUS) may help evaluate segmental differences in renal perfusion better than Doppler Ultrasound and thus help direct the biopsy to the most abnormal part of the renal cortex. This should maximize detection and increase the od...
What is the current status of trial NCT02625428?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2015-11. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02625428?
The interventions under investigation include: Contrast-enhanced ultrasound (CEUS) (DIAGNOSTIC_TEST), Optison (DRUG), Ultrasound (US) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT02625428?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.